Dipeptidyl Peptidase IV in Angiotensin-converting Enzyme Inhibitor Associated Angioedema

Overview

Journal Hypertension

Date 2007 Nov 21

PMID 18025295

Citations 52

Authors

James Brian Byrd

Karine Touzin

Saba Sile

James V Gainer

Chang Yu

John Nadeau

Albert Adam

Nancy J Brown

Affiliations

Soon will be listed here.

Abstract

Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with angiotensin-converting enzyme inhibitor-associated angioedema. This case-control study tested the hypothesis that dipeptidyl peptidase IV activity and antigen are decreased in sera of patients with a history of angiotensin-converting enzyme inhibitor-associated angioedema. Fifty subjects with a history of angiotensin-converting enzyme inhibitor-associated angioedema and 176 angiotensin-converting enzyme inhibitor-exposed control subjects were ascertained. Sera were assayed for angiotensin-converting enzyme activity, aminopeptidase P activity, aminopeptidase N activity, dipeptidyl peptidase IV activity, and antigen and the ex vivo degradation half-lives of bradykinin, des-Arg(9)-bradykinin, and substance P in a subset. The prevalence of smoking was increased and of diabetes decreased in case versus control subjects. Overall, dipeptidyl peptidase IV activity (26.6+/-7.8 versus 29.6+/-7.3 nmol/mL per minute; P=0.026) and antigen (465.8+/-260.8 versus 563.1+/-208.6 ng/mL; P=0.017) were decreased in sera from individuals with angiotensin-converting enzyme inhibitor-associated angioedema compared with angiotensin-converting enzyme inhibitor-exposed control subjects without angioedema. Dipeptidyl peptidase IV activity (21.5+/-4.9 versus 29.8+/-6.7 nmol/mL per minute; P=0.001) and antigen (354.4+/-124.7 versus 559.8+/-163.2 ng/mL; P=0.003) were decreased in sera from cases collected during angiotensin-converting enzyme inhibition but not in the absence of angiotensin-converting enzyme inhibition. The degradation half-life of substance P correlated inversely with dipeptidyl peptidase IV antigen during angiotensin-converting enzyme inhibition. Environmental or genetic factors that reduce dipeptidyl peptidase IV activity may predispose individuals to angioedema.

Citing Articles

Adaptation and Linguistic Validation of Angioedema PROMs in Latvian for Assessing Recurrent Angioedema.

Lapina L, Kanepa A, Zolovs M, Buttgereit T, Kurjane N J Clin Med. 2025; 14(4).

PMID: 40004905 PMC: 11856593. DOI: 10.3390/jcm14041375.

Five-Membered Nitrogen Heterocycles Angiotensin-Converting Enzyme (ACE) Inhibitors Induced Angioedema: An Underdiagnosed Condition.

Papapostolou N, Gregoriou S, Katoulis A, Makris M Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543146 PMC: 10974338. DOI: 10.3390/ph17030360.

Prediction and prevention of ACE-inhibitor-induced angioedema-an unmet clinical need in management of hypertension.

Rubin S, Tomaszewski M Hypertens Res. 2023; 47(2):257-260.

PMID: 37945891 DOI: 10.1038/s41440-023-01491-9.

Multidisciplinary Prophylactic Strategies for Recurrence of Laryngeal Edema After Tooth Extraction in a Patient With Hereditary Angioedema: A Case Report.

Honda D, Ohsawa I, Aizawa M, Miyamoto I, Uzawa K, Asanuma K Cureus. 2023; 15(10):e46869.

PMID: 37841987 PMC: 10567609. DOI: 10.7759/cureus.46869.

Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

Douillard M, Deheb Z, Bozon A, Raison-Peyron N, Dereure O, Moulis L World Allergy Organ J. 2023; 16(8):100809.

PMID: 37638360 PMC: 10458346. DOI: 10.1016/j.waojou.2023.100809.

References

Bork K, Frank J, Grundt B, Schlattmann P, Nussberger J, Kreuz W . Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol. 2007; 119(6):1497-503. DOI: 10.1016/j.jaci.2007.02.012. View

Brown N, Snowden M, Griffin M . Recurrent angiotensin-converting enzyme inhibitor--associated angioedema. JAMA. 1997; 278(3):232-3. DOI: 10.1001/jama.278.3.232. View

Byrd J, Shreevatsa A, Putlur P, Foretia D, McAlexander L, Sinha T . Dipeptidyl peptidase IV deficiency increases susceptibility to angiotensin-converting enzyme inhibitor-induced peritracheal edema. J Allergy Clin Immunol. 2007; 120(2):403-8. DOI: 10.1016/j.jaci.2007.04.012. View

van der Velden V, Naber B, van Hal P, Overbeek S, Hoogsteden H, Versnel M . Peptidase activities in serum and bronchoalveolar lavage fluid from allergic asthmatics--comparison with healthy non-smokers and smokers and effects of inhaled glucocorticoids. Clin Exp Allergy. 1999; 29(6):813-23. DOI: 10.1046/j.1365-2222.1999.00550.x. View

Mentlein R, Gallwitz B, Schmidt W . Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993; 214(3):829-35. DOI: 10.1111/j.1432-1033.1993.tb17986.x. View

Pesquero J, Jubilut G, Lindsey C, Paiva A . Bradykinin metabolism pathway in the rat pulmonary circulation. J Hypertens. 1992; 10(12):1471-8. DOI: 10.1097/00004872-199210120-00006. View

Russell J, Chi H, Lantry L, Stephens R, Ward P . Substance P and neurokinin A metabolism by cultured human skeletal muscle myocytes and fibroblasts. Peptides. 1996; 17(8):1397-403. DOI: 10.1016/s0196-9781(96)00201-x. View

Kopp U, Farley D, Smith L . Bradykinin-mediated activation of renal sensory neurons due to prostaglandin-dependent release of substance P. Am J Physiol. 1997; 272(6 Pt 2):R2009-16. DOI: 10.1152/ajpregu.1997.272.6.R2009. View

Ahren B, Gomis R, Standl E, Mills D, Schweizer A . Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004; 27(12):2874-80. DOI: 10.2337/diacare.27.12.2874. View

10.

Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, AGOSTONI A . Plasma bradykinin in angio-oedema. Lancet. 1998; 351(9117):1693-7. DOI: 10.1016/S0140-6736(97)09137-X. View

11.

Elgun S, Keskinege A, Akan H, Karaca L . Serum dipeptidyl peptidase IV activity correlates with the T-cell CD26 antigen. Clin Chem Lab Med. 1999; 37(8):839-40. DOI: 10.1515/CCLM.1999.126. View

12.

Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P . Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care. 2002; 25(5):869-75. DOI: 10.2337/diacare.25.5.869. View

13.

Mari A, Sallas W, He Y, Watson C, Ligueros-Saylan M, Dunning B . Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab. 2005; 90(8):4888-94. DOI: 10.1210/jc.2004-2460. View

14.

Duan Q, Nikpoor B, Dube M, Molinaro G, Meijer I, Dion P . A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. Am J Hum Genet. 2005; 77(4):617-26. PMC: 1275610. DOI: 10.1086/496899. View

15.

Pi-Sunyer F, Schweizer A, Mills D, Dejager S . Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. Diabetes Res Clin Pract. 2007; 76(1):132-8. DOI: 10.1016/j.diabres.2006.12.009. View

16.

Charbonnel B, Karasik A, Liu J, Wu M, Meininger G . Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006; 29(12):2638-43. DOI: 10.2337/dc06-0706. View

17.

Rosenstock J, Kim S, Baron M, Camisasca R, Cressier F, Couturier A . Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2007; 9(2):175-85. DOI: 10.1111/j.1463-1326.2006.00698.x. View

18.

Mannucci E, Pala L, Ciani S, Bardini G, Pezzatini A, Sposato I . Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia. 2005; 48(6):1168-72. DOI: 10.1007/s00125-005-1749-8. View

19.

Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A . Angiotensin-converting enzyme inhibitor-associated angioedema is characterized by a slower degradation of des-arginine(9)-bradykinin. J Pharmacol Exp Ther. 2002; 303(1):232-7. DOI: 10.1124/jpet.102.038067. View

20.

Blais Jr C, Rouleau J, Brown N, Lepage Y, Spence D, Munoz C . Serum metabolism of bradykinin and des-Arg9-bradykinin in patients with angiotensin-converting enzyme inhibitor-associated angioedema. Immunopharmacology. 1999; 43(2-3):293-302. DOI: 10.1016/s0162-3109(99)00133-2. View